Health Technology Assessment (HTA) Review Implementation Advisory Group (IAG); Interim Report Released
The IAG led by Chair, Professor Andrew Wilson is helping to guide critical reforms in response to the HTA Review Report. The interim report provides early insights from the advisory group’s work to date. The final report and implementation roadmap are due to go to the government in January 2026.
In response to the findings of the IAG’s Interim Report, the Federal Government has announced that it is taking immediate actions to:
commence consultation on trialling new ways to streamline assessment of medicines
begin a rolling review of the Pharmaceutical Benefits Advisory Committee (PBAC) Guidelines prioritising comparator selection and discount rate as the first areas for review
undertake rapid research into areas of high unmet clinical need and high added therapeutic value, including definitions of these terms
develop a HTA stakeholder engagement framework with a focus on improving consumer and patient engagement
hold bi-annual stakeholder meetings to consider specific issues related to medicines for First Nations people
Posted 5 September